Pre-made Romilkimab biosimilar ( Bispecific Dual Variable Domain IG, anti-IL13;IL4 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-492
Anti-IL13;IL4 therapeutic antibody (Pre-made Romilkimab biosimilar,Bispecific Dual Variable Domain IG) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Romilkimab (SAR156597), however, “is an engineered, humanised, bispecific immunoglobulin-G4 antibody that binds and neutralizes IL-4/IL-13 making it ideal for exploration in fibrosis,” the researchers explain.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-IL13;IL4 therapeutic antibody (Pre-made Romilkimab biosimilar,Bispecific Dual Variable Domain IG)|
|Format||Bispecific Dual Variable Domain IG|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None;None|
|99% SI Structure||None;None|
|95-98% SI Structure||None;None|
|Conditions Active||Systemic scleroderma|
|Conditions Discontinued||Idiopathic pulmonary fibrosis|